Table 1.
Anti-HIV-1 activity of TAK-779 in PBMCs
| Virus | Tropism | EC50, μM | EC90, μM | CC50, μM |
|---|---|---|---|---|
| Ba-L | R5 | 0.0037 ± 0.0006 | 0.0128 ± 0.0019 | >20 |
| KK | R5 | 0.0016 ± 0.0005 | 0.0208 ± 0.0151 | |
| HHA | R5 | 0.0032 ± 0.0006 | 0.0075 ± 0.0017 | |
| CTV | R5 | 0.0035 ± 0.0015 | 0.0270 ± 0.0048 | |
| IIIB | X4 | >20 | ||
| SW | X4 | >20 | ||
| MZ | X4 | >20 |
EC50 and EC90 were defined as the concentrations of TAK-779 required to reduce p24 antigen production in culture supernatants of HIV-1-infected PBMCs by 50 and 90%, respectively. CC50 was defined as the concentration of TAK-779 required to reduce the viability and proliferation of mock-infected PBMCs by 50%. KK, HHA, and CTV strains are R5 HIV-1 clinical isolates whereas SW and MZ strains are X4 HIV-1 clinical isolates. All data represent means ± SEM of at least three separate experiments.